comparemela.com

Latest Breaking News On - Karolinska institute in huddinge - Page 1 : comparemela.com

Newly discovered gene variant linked to protection against abdominal obesity

American researchers believe they have identified a rare gene mutation that protects against abdominal obesity and metabolic syndrome. The ambition is that the discovery will lead to new treatments that can help reduce the risk of type 2 diabetes and coronary artery disease.

LIDDS AB: International Journal of Pharmaceutics Publishes Study on the NanoZolid Technology for Local Release of Biomolecules

(0) UPPSALA, SWEDEN - LIDDS AB (publ) announced today that the journal International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been performed in collaboration with the Karolinska Institute in Huddinge, Sweden and Truly labs in Lund, Sweden. The study confirms that proteins are released from NanoZolid depots with maintained bio-functionality, illustrated by protein targeting to tumor cell receptors. The investigation was performed with fluorescence-imaging. The NanoZolid technology has during the last years been shown to enable a controlled release of a wide range of drugs following a single injection, resulting in stable and pharmacologically validated effects over a desired time period. In this study, a fluorescence-labelled model substance, Epidermal Growth Factor (EGF) protein, was used and followed longitudinally in mice after subcutaneous injections of the NanoZolid depot implants. The labelled EGF accumulated

Investegate |LIDDS AB Announcements | LIDDS AB: International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules

International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the journal International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been performed in collaboration with the Karolinska Institute in Huddinge, Sweden and Truly labs in Lund, Sweden. The study confirms that proteins are released from NanoZolid® depots with maintained bio-functionality, illustrated by protein targeting to tumor cell receptors. The investigation was performed with fluorescence-imaging.                                                     The NanoZolid® technology has during the last years been shown to enable a controlled release of a wide range of drugs following a single injection, resulting in stable and pharmacologically validated effects over a desired time period. In th

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.